Cases That Test Your Skills

A 95-year-old man with treatment-resistant depression

Author and Disclosure Information

 

References

Evidence supports using ECT in older patients

Multiple studies have found that ECT is a rapid, safe, and efficacious intervention for treating older persons with depression. Patients age >60 who receive ECT plus pharma­cotherapy have lower HAM-D scores than those receiving pharmacotherapy alone.5 Overall, the rates of remission for depression range from 50% to 70%; yet geriatric patients who receive only ECT have response rates around 90%.6 Older age, presence of psychotic symptoms, and shorter duration of illness can predict a rapidly positive ECT response.7

When treated with ECT, older patients, including those age >85, have fewer subsequent episodes of depression compared with those who receive pharmacotherapy alone.1 Older individuals with physical illness or cognitive impairment respond to and tolerate ECT much like younger patients.6 Older patients receiving ECT may experience less cognitive decline than younger ones.7 Those in their ninth decade of life with treatment-resistant depression, psychotic features, and post-stroke depression often respond robustly with improvement following ECT.8

Remission rates also depend on the technique of administration. Interactions between electrode placement and stimulus parameter dosage affect efficacy and adverse effects.9 Right-sided, unilateral ECT induces less cognitive dysfunction compared with bilateral electrode placement,9 but bilateral ECT is more clinically effective.10 However, the efficacy of right-sided ECT is more dose-sensitive, and some data suggest that suboptimal response is due to insufficient stimulus dosages.11 One double-blind randomized controlled trial documented that when using a high-dose stimulus parameter, unilateral ECT is as effective as bilateral ECT.12 When there is a suboptimal response to unilateral ECT, bilateral ECT might be beneficial.12,13 For preventing relapse in older patients, increasing the interval between ECT treatments is more effective than stopping ECT abruptly.13

Indications of ECT

ECT is indicated for patients with severe depression, mania, and other conditions (Table).14 The most common indication for ECT in older persons is a history of treatment-resistant depression, with melancholia, psychosis, or suicidal ideations.1-6,12 There are also age-related and clinical factors to consider with ECT. This treatment provides a safe, rapid remission for patients age >65, even after adjusting for somatic conditions, duration of illness, medication resistance, or case severity.15 Compared with younger patients, older adults may not tolerate antidepressants as well because of age-related pharmacokinetic alterations, including increased sensitivity to anticholinergic and/or hypotensive effects.1

Factors that favor ECT include a previous good response to it; patient preference; and an indication for rapid intervention, such as suicidality, catatonia, dehydration, malnutrition, or a suboptimal result from pharmacotherapy.3 Mortality among individuals age >85 who receive ECT reportedly is lower than that among their counterparts who receive alternative treatments.16 ECT has been administered safely and effectively in patients with comorbid medical illnesses such as stroke, cerebral aneurysm, cardiovascular disease with ischemia or arrhythmia, dementia, and osteoporosis.17

Recommended Reading

A concise guide to monoamine oxidase inhibitors
MDedge Psychiatry
Dietary restrictions with MAOIs
MDedge Psychiatry
‘Tea with Freud’: Engaging, authentic, but nonanalytic
MDedge Psychiatry
Antidepressant therapy is too often tardy
MDedge Psychiatry
Self-harm on rise in U.S. among girls aged 10-14
MDedge Psychiatry
Helping patients process sexual harassment
MDedge Psychiatry
Physician health programs: ‘Diagnosing for dollars’?
MDedge Psychiatry
Poststroke depression raises risk of cerebrovascular death 35-fold
MDedge Psychiatry
Inside the ‘mad rush’ for ketamine treatment
MDedge Psychiatry
More evidence backs adjunctive intranasal esketamine for refractory depression
MDedge Psychiatry